ES2624835T3 - Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos - Google Patents

Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos Download PDF

Info

Publication number
ES2624835T3
ES2624835T3 ES10806238.1T ES10806238T ES2624835T3 ES 2624835 T3 ES2624835 T3 ES 2624835T3 ES 10806238 T ES10806238 T ES 10806238T ES 2624835 T3 ES2624835 T3 ES 2624835T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
acid sequence
chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10806238.1T
Other languages
English (en)
Spanish (es)
Inventor
Tatsuki Yokoseki
Yasuhide Okamoto
Makoto Umeda
Naofumi Takamatsu
Toshiyuki Ito
Yukiho Imai
Shinobu Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunas Pharma Inc
Original Assignee
Immunas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunas Pharma Inc filed Critical Immunas Pharma Inc
Application granted granted Critical
Publication of ES2624835T3 publication Critical patent/ES2624835T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10806238.1T 2009-08-06 2010-08-05 Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos Active ES2624835T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23179709P 2009-08-06 2009-08-06
US231797P 2009-08-06
US28253310P 2010-02-26 2010-02-26
US282533P 2010-02-26
PCT/JP2010/004925 WO2011016238A1 (en) 2009-08-06 2010-08-05 Antibodies that specifically bind to a beta oligomers and use thereof

Publications (1)

Publication Number Publication Date
ES2624835T3 true ES2624835T3 (es) 2017-07-17

Family

ID=43544147

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10806238.1T Active ES2624835T3 (es) 2009-08-06 2010-08-05 Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos

Country Status (7)

Country Link
US (1) US8858949B2 (enExample)
EP (1) EP2462161B1 (enExample)
JP (1) JP5769316B2 (enExample)
CN (1) CN102574915B (enExample)
DK (1) DK2462161T3 (enExample)
ES (1) ES2624835T3 (enExample)
WO (1) WO2011016238A1 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2099826B1 (en) * 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid antibody and uses thereof
EP2210901A4 (en) * 2007-10-19 2012-04-25 Immunas Pharma Inc FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
EP3121277B1 (en) 2008-02-08 2018-04-11 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
US20110182809A1 (en) * 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
EP3521309A1 (en) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
JP2014505057A (ja) 2011-01-10 2014-02-27 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 幹細胞因子阻害剤
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
GB201110938D0 (en) * 2011-06-27 2011-08-10 Iti Scotland Ltd Compounds
US20140377288A1 (en) * 2011-09-16 2014-12-25 The Board Of Regents Of The University Of Texas System Compositions and methods related to dna damage repair
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
WO2014100439A2 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015006554A1 (en) * 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
WO2015054600A2 (en) * 2013-10-10 2015-04-16 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CA2938152A1 (en) * 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
US10401368B2 (en) 2014-03-20 2019-09-03 Pdl Biopharma, Inc. Antibodies and methods for the detection of cell death
EP3662928A1 (en) * 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
MY198017A (en) 2014-08-19 2023-07-26 Merck Sharp & Dohme Anti-tigit antibodies
KR20170056521A (ko) 2014-09-16 2017-05-23 오바사이언스, 인크. 항-vasa 항체, 및 이것의 제조 및 사용 방법
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2971517A1 (en) * 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
US10654917B2 (en) * 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
WO2016137947A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-amyloid-beta antibodies
WO2016145022A1 (en) * 2015-03-11 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-dc-hil antibodies for cancer diagnosis, prognosis and therapy
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
WO2016160618A2 (en) * 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
EP3307784B1 (en) * 2015-06-10 2021-12-22 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2017030823A2 (en) * 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
RU2021133819A (ru) * 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
HK1259325A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
AU2017234528B2 (en) * 2016-03-16 2023-09-28 Nathan Bartlett Neutralizing monoclonal antibodies to IL-25 and uses thereof
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US10815306B2 (en) 2016-06-16 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD81
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018098370A1 (en) * 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
CN106749657A (zh) * 2016-12-13 2017-05-31 中国农业科学院哈尔滨兽医研究所 一种抗体信号肽及其应用
US11458169B2 (en) 2017-02-22 2022-10-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. TIM3-binding chimeric antigen receptors
WO2018158398A1 (en) * 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3608335A4 (en) * 2017-04-05 2020-04-29 XDCExplorer (Shanghai) Co., Ltd. HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS
US11161897B2 (en) * 2017-07-17 2021-11-02 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2019217833A1 (en) * 2018-05-10 2019-11-14 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
WO2019231957A1 (en) * 2018-05-30 2019-12-05 National Health Research Institutes Anti-abeta antibodies and uses thereof
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
JP7623939B2 (ja) * 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
EP3852779A4 (en) * 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
JP2022523502A (ja) * 2019-01-29 2022-04-25 シャンハイ ジャオ トン ユニバーシティ キメラ抗原受容体およびその使用
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN113784983B (zh) * 2019-03-02 2024-04-16 小利兰·斯坦福大学托管委员会 Cd93特异性治疗性抗原结合蛋白及其使用方法
WO2020193644A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
CN110343180B (zh) * 2019-07-25 2021-03-30 北京免疫方舟医药科技有限公司 抗ctla-4抗体及其应用
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN111793136A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种nmp22抗体对及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
US20230340089A1 (en) * 2020-05-14 2023-10-26 City Of Hope Smc1a antibodies and uses thereof
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
JP2023536629A (ja) * 2020-08-04 2023-08-28 エグゼリクシス， インコーポレイテッド Ｃｄ４７結合性作用剤およびその使用
KR20230047492A (ko) * 2020-08-18 2023-04-07 오메로스 코포레이션 보체 인자 d의 검출을 위한 단클론성 항체, 조성물 및 방법
CN112778419A (zh) * 2021-02-01 2021-05-11 重庆中元汇吉生物技术有限公司 抗ck-mb的抗体或其抗原结合部分及其应用
US20240117047A1 (en) * 2021-02-11 2024-04-11 The Regents Of The University Of California Monoclonal antibodies specific for human ror1
CN113075398A (zh) * 2021-03-23 2021-07-06 中国医学科学院输血研究所 一种血浆中特异性IgG抗体的定量测定方法
WO2023076926A1 (en) * 2021-10-26 2023-05-04 Bach Diagnostics Inc. Lateral flow assay for the diagnosis of dermatmycoses
KR20250102074A (ko) * 2022-11-08 2025-07-04 페인스 테라퓨틱스 인코포레이티드 항-5t4 항체 및 이의 용도
US12534540B2 (en) * 2023-01-23 2026-01-27 Clemson University Research Foundation CYP1A1-targeted monoclonal antibody with reactivity across vertebrate taxa
WO2024159174A1 (en) * 2023-01-27 2024-08-02 The United States Goverment As Represented By The Department Of Veterans Affairs Compositions for treating tauopathies and methods of use thereof
EP4673476A1 (en) * 2023-02-28 2026-01-07 Mayo Foundation for Medical Education and Research Molecules that bind to b-cell activating factor receptor polypeptides
CN119306826B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒
WO2025044931A1 (zh) * 2023-08-25 2025-03-06 康诺亚生物医药科技（成都）有限公司 阿尔茨海默病治疗剂的开发和应用
CN119613538B (zh) * 2024-12-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 抗h10亚型流感病毒血凝素蛋白中和性单克隆抗体1e10及其应用
CN120209138B (zh) * 2025-05-29 2025-10-03 杭州广科安德生物科技有限公司 Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
WO2003014162A1 (en) 2001-08-03 2003-02-20 Medical & Biological Laboratories Co., Ltd. ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
CA2572602A1 (en) 2004-07-02 2006-02-09 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid .beta. (abeta)
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
NZ554725A (en) 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
CA2593846A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
ATE458754T1 (de) 2005-03-05 2010-03-15 Abbott Gmbh & Co Kg Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper
WO2006137354A1 (ja) 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
EP1749839A1 (en) 2005-07-22 2007-02-07 Novoplant GmbH Antigen binding polypeptides against F4(K88) fimbriae
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
EP2210901A4 (en) 2007-10-19 2012-04-25 Immunas Pharma Inc FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
EP3121277B1 (en) 2008-02-08 2018-04-11 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof

Also Published As

Publication number Publication date
DK2462161T3 (en) 2017-06-06
EP2462161A1 (en) 2012-06-13
US20120177664A1 (en) 2012-07-12
JP5769316B2 (ja) 2015-08-26
EP2462161A4 (en) 2013-05-29
CN102574915B (zh) 2014-10-22
WO2011016238A1 (en) 2011-02-10
CN102574915A (zh) 2012-07-11
JP2013500941A (ja) 2013-01-10
EP2462161B1 (en) 2017-03-08
US8858949B2 (en) 2014-10-14

Similar Documents

Publication Publication Date Title
ES2624835T3 (es) Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
ES2614949T3 (es) Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
US9090679B2 (en) Antibodies that specifically bind to A beta oligomers and use thereof
US9090680B2 (en) Antibodies that specifically bind to abeta oligomers and uses thereof
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
US12071472B2 (en) Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
CA2702880A1 (en) Antibody capable of specifically binding to a beta oligomer, and use thereof
WO2011045945A1 (ja) アミロイドβのターン構造を認識する抗体
US9085614B2 (en) Antibodies that specifically bind to Aβ oligomers and uses thereof